Therefore, in this study, we decided to analyze the activating mutations of EZH2 at Y641 in ctDNA in tumor tissue and peripheral blood, demonstrating the utility of the detection as a prognostic marker, which could also be helpful in identifying patients with DLBCL who can benefit from target therapies against EZH2. The gene discussed is EZH2; the disease is neoplasm.